|
Senior Scientist, Chronic Disease, Ottawa Hospital Research Institute
Infectious Disease Specialist
Associate Professor, Faculty of Medicine, University of Ottawa
Biographical Sketch
Dr. Angel graduated from medical school at the University of Toronto in 1988 which was followed by an internal medicine residency in Toronto. After one year as the chief medical resident at St. Paul's Hospital in Vancouver, he did his clinical and research infectious diseases training at the New England Medical Centre/Tufts University in Boston supported by an MRC fellowship. In 1995, Dr. Angel joined the Division of Infectious Diseases, Department of Medicine at the Ottawa General Hospital. Since that time he has been involved in basic science and clinical research as well as patient care. His research is focused in three main areas 1) basic science: mechanisms of HIV-induced cellular immune dysfunction, 2) translational research: the impact of antiretroviral and immune-based therapies on immune function in patients with HIV infection, and 3) clinical trials: studies of immune-based therapies including HIV vaccines, in patients with HIV infection. Dr. Angel is currently an Associate Professor of Medicine at the University of Ottawa and a Clinician Scientist in the Ottawa Hospital Research Institute. He is supported by a Scientist Salary Award from the AIDS Program Committee, Ontario Ministry of Health and has research funding from CIHR and the Ontario HIV Treatment Network (OHTN).
Research Interests:
HIV immunopathogenesis
Immune based therapies for HIV Infection
Major Research Activities:
1) Studies on the mechanisms of HIV induced immune dysfunction
2) Studies on immune restoration with effective anti-HIV therapy
3) Studies on immune based therapies and vaccines in HIV infection
Major Awards/Affiliations:
Scientist Salary Award, AIDS Program, Ontario Ministry of Health, 1999-2004
Canadian Foundation for Innovation, New Opportunities Investigator 1999
Canadian Association for HIV Research, Council Member, 1999-2001
CANVAC Member 2001
Most Recent Publications (provided by The Ottawa Hospital Library Database)
Ma W;Mishra S;Gajanayaka N;Angel JB;Kumar A;, (2009 Mar 20), HIV-1 Nef inhibits lipopolysaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFkappaB in human monocytic cells, Journal of Biological Chemistry, Vol.284, Issue 12, 7578-7587 -> view abstract
Harris M;Angel JB;Baril JG;Rachlis A;Trottier B;, (2009), Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults, Canadian Journal of Infectious Diseases and Medical Microbiology, Vol.20, Issue 2, -> view abstract
Faucher S;Crawley AM;Decker W;Sherring A;Bogdanovic D;Ding T;Bergeron M;Angel JB;Sandstrom P;, (2009), Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma, PLoS ONE [Electronic Resource], Vol.4, Issue 8, e6690 -> view abstract
Crawley AM;Katz T;Parato K;Angel JB;, (2009), IL-2 receptor γ chain cytokines differentially regulate human CD8+ CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis, International Immunology, Vol.21, Issue 1, 29-42 -> view abstract
Landovitz RJ;Angel JB;Hoffmann C;Horst H;Opravil M;Long J;Greaves W;Fatkenheuer G;, (2008 Oct 15), Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection, Journal of Infectious Diseases, Vol.198, Issue 8, 1113-1122 -> view abstract
Shepard BD;Loutfy MR;Raboud J;Mandy F;Kovacs CM;Diong C;Bergeron M;Govan V;Rizza SA;Angel JB;Badley AD;, (2008 Jun 1), Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection, Journal of Acquired Immune Deficiency Syndromes: JAIDS, Vol.48, Issue 2, 149-155 -> view abstract
Angel JB;Cooper CL;Clinch J;Young CD;Chenier A;Parato KG;Lautru M;Davis H;Cameron DW;, (2008 Aug 12), CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection, J Immune Based Ther Vaccines , Vol.6, Issue 1, 4 -> view abstract
Cooper CL;Angel JB;Seguin I;Davis HL;Cameron DW;, (2008 Apr 15), CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years, Clin Infect Dis, Vol.46, Issue 8, 1310-1314 -> view abstract
D'Egidio GE;Kravcik S;Cooper CL;Cameron DW;Fergusson DA;Angel JB;, (2008), Withdrawal of Pneumocystis prophylaxis: Authors' reply [9], AIDS, Vol.22, Issue 2, 324
Beique L;Giguere P;la Porte CJ;Angel J;, (2007 Sep), Interactions between protease inhibitors and acid-reducing agents: a systematic review60, HIV Medicine, Vol.8, Issue 6, 335-345 -> view abstract
Note: This is not a complete list of publications. More publications may be available in The Ottawa Hospital Library database and Pubmed (search by last name and initials).
| |
General Campus
(see 
